Eupraxia Pharmaceuticals ... (EPRX)
Eupraxia Pharmaceuticals Statistics
Share Statistics
Eupraxia Pharmaceuticals has 35.85M shares outstanding. The number of shares has increased by 0.64% in one year.
| Shares Outstanding | 35.85M |
| Shares Change (YoY) | 0.64% |
| Shares Change (QoQ) | 0.64% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 27.73M |
| Failed to Deliver (FTD) Shares | 2.52K |
| FTD / Avg. Volume | 17.08% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -5.28. Eupraxia Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -5.28 |
| PS Ratio | 0 |
| Forward PS | 1.7 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Eupraxia Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.1, with a Debt / Equity ratio of 0.
| Current Ratio | 11.1 |
| Quick Ratio | 11.1 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.13M |
| Employee Count | 33 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -89.67K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 28.29% in the last 52 weeks. The beta is 1.54, so Eupraxia Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.54 |
| 52-Week Price Change | 28.29% |
| 50-Day Moving Average | 3.56 |
| 200-Day Moving Average | 3.01 |
| Relative Strength Index (RSI) | 48.03 |
| Average Volume (20 Days) | 14.76K |
Income Statement
| Revenue | n/a |
| Gross Profit | -209.91K |
| Operating Income | -37.2M |
| Net Income | -37.39M |
| EBITDA | -36.75M |
| EBIT | -36.9M |
| Earnings Per Share (EPS) | -1.58 |
Balance Sheet
The company has 33.1M in cash and 71.86K in debt, giving a net cash position of 33.03M.
| Cash & Cash Equivalents | 33.1M |
| Total Debt | 71.86K |
| Net Cash | 33.03M |
| Retained Earnings | -131M |
| Total Assets | 34.94M |
| Working Capital | 31.33M |
Cash Flow
In the last 12 months, operating cash flow was -29.99M and capital expenditures -104.23K, giving a free cash flow of -30.1M.
| Operating Cash Flow | -29.99M |
| Capital Expenditures | -104.23K |
| Free Cash Flow | -30.1M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EPRX is $9, which is 179.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 179.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 14.64 |
| Piotroski F-Score | 1 |